디피리다몰
디피리다몰 · 다이피리다몰 · DIPYRIDAMOL · Dipiridamol · dypyridamole · Anginal · persantin · Persantine
식별자 및 물리적 특성
| CAS No. | 58-32-2 |
|---|---|
| 분자식 | C24H40N8O4 |
| 평균 분자량 | 504.6 g/mol |
| 단동위원소 질량 | 504.31725176 g/mol |
| SMILES | OCCN(CCO)c1nc(N2CCCCC2)c2nc(N(CCO)CCO)nc(N3CCCCC3)c2n1 |
| InChIKey | IZEKFCXSFNUWAM-UHFFFAOYSA-N |
| PubChem CID | 3108 |
| ChEMBL | CHEMBL932 |
| ChEBI | CHEBI:4653 |
| EC No. | 200-374-7 |
| DTXSID | DTXSID6040668 |
| 현지명 | 디피리다몰 |
화학 및 물리적 성질
| XLogP | 0.7 |
|---|---|
| 극성 표면적 | 145 |
| 수소 결합 공여자 수 | 4 |
| 수소 결합 수용자 수 | 12 |
| 회전 가능 결합 수 | 12 |
| 무거운 원자 수 | 36 |
| 형식 전하 | 0 |
| 복잡도 | 561 |
| 의약품 | Pharmaceuticals -> Listed in ZINC15Pharmaceuticals -> Used in Switzerland |
| LogP(분배 계수) | 1.5 |
| 용해도 | Slightly9.22e-01 g/L10.7 [ug/mL] (The mean of the results at pH 7.4)DMSO: 용해될 수 있다 |
| Human Drugs | BreastfeedingLactationMilk, HumanPhosphodiesterase InhibitorsVasodilator AgentsPlatelet Aggregation InhibitorsFDA approved drugs -> Active ingredientPharmaceuticals |
| 녹는점 | 163 °C165-166 °C (lit.) |
| Physical Description | Solid |
| Collision Cross Section | 223.9 Ų [M+H]+ [CCS Type: TWMethod: calibrated with polyalanine and drug standards]227.5 Ų [M+H]+ [CCS Type: TWMethod: Major Mix IMS/Tof Calibration Kit (Waters)]222.83 Ų [M+H]+ [CCS Type: TW |
| 끓는 점 | 593.96°C (rough estimate) |
| 밀도 | 1.2046 (rough estimate) |
| 굴절률 | 1.6910 (estimate) |
| 저장 조건 | room temp |
| 물리적 상태 | 가루 |
| pKa(산도 계수) | pKa 6.4 (Uncertain) |
| 색상 | 노란색 |
| 용해도 | 클로로포름, 메탄올, 묽은 산, 에탄올에 용해됩니다. 물에 약간 용해됩니다. |
| Merck | 14,3346 |
| 안정성 | 제공된 대로 구매일로부터 1년 동안 안정적입니다. DMSO 또는 에탄올 용액은 -20°C에서 최대 3개월 동안 보관할 수 있습니다. |
| InChI | InChI=1S/C24H40N8O4/c33-15-11-31(12-16-34)23-26-20-19(21(27-23)29-7-3-1-4-8-29)25-24(32(13-17-35)14-18-36)28-22(20)30-9-5-2-6-10-30/h33-36H,1-18H2 |
| InChIKey | IZEKFCXSFNUWAM-UHFFFAOYSA-N |
| SMILES | C1(N(CCO)CCO)=NC(N2CCCCC2)=C2N=C(N(CCO)CCO)N=C(N3CCCCC3)C2=N1 |
| NIST | Pyrimidine, 2,6-bis(diethanolamino)-4,8-dipiperidino-pyrimido-(5,4-d)-(58-32-2) |
화학적 성질
Yellow Powder
안전 및 규제
| GHS 분류 | WarningH315 (98.7%): Causes skin irritation [Warning Skin corrosion/irritation]P261, P264, P264+P265, P271, P280, P302+P352, P304+P340, P305+P351+P338, P319, P321, P332+P317, P337+P317, P362+P364, P403+P233, P405, and P501 (click each P-code to see the statement)Aggregated GHS information provided per 75 reports by companies from 8 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies. |
|---|---|
| 기타 안전 정보 | IMAP assessments - Ethanol, 2,2',2'',2'''-[(4,8-di-1-piperidinylpyrimido[5,4-d]pyrimidine-2,6-diyl)dinitrilo]tetrakis-: Environment tier I assessment |
| Hazard Classes and Categories | Skin Irrit. 2 (98.7%) |
| Hepatotoxicity | Dipyridamole has been associated with a low rate of serum enzyme elevations during therapy, but in large clinical trials the frequency of liver enzyme abnormalities was similar with dipyridamole therapy as with placebo. Cases of clinically apparent acute liver injury from dipyridamole have not been published although hepatitis is listed as a potential side effect in the product label. The clinical features of the liver injury linked to dipyridamole have not been described. |
| 유해 작용 | The most frequently reported adverse effects include: |
| 독성 요약 | Signs and Symptoms of Overdose |
| Drug Induced Liver Injury | Drug Induced Liver Injury Rank (DILIrank 2.0)DipyridamoleAmbiguous-DILI-concern3Warnings & precautionsDOI:10.1016/j.drudis.2016.02.015 |
| Effects During Pregnancy and Lactation | ◉ Summary of Use during Lactation |
| 수질 위해 등급(WGK) | 2 |
| RTECS 번호 | KK7450000 |
| 독성 | LD50 in rats: 8.4 g/kg orally208 mg/kg i.v. (Takenaka) |
| 관세 코드 | 29335990 |
| 위험 문구(R) |
용도
용도
Dipyridamole prevents platelets sticking to the replacement heart valve and causing a blood clot on the valve. It is used to dilate blood vessels in people with peripheral arterial disease and coronary artery disease. This compound has been shown to suppress high glucose-induced osteopontin mRNA expression and protein secretion, as well as inhibit cAMP and cGMP hydrolysis. Research indicates that Dipyridamole is a non-specific nucleoside transport inhibitor with the ability to increase the effects of adenosine in sinoatrial and atrioventricular nodes. Dipyridamole is an inhibitor of ENT1 and ENT2.
일반 설명
Dipyridamole, 2,2',2',2'''-[(4,8-di-1piperidinylpyrimido[5,4-d]pyrimidine-2,6-diyl)dinitrilo]-tetrakisethanol (Persantine), may be used for coronary andmyocardial insufficiency. Its biggest use today, however, isas an antithrombotic in patients with prosthetic heart valves.It is a bitter, yellow, crystalline powder, soluble in diluteacids, methanol, or chloroform. A formulation containingdipyridamole and aspirin (Aggrenox) is currently beingmarketed as an antithromobotic.Dipyridamole is a long-acting vasodilator. Its vasodilatingaction is selective for the coronary system; it is indicatedfor long-term therapy of chronic angina pectoris. Thedrug also inhibits adenosine deaminase in erythrocytesand interferes with the uptake of the vasodilator adenosineby erythrocytes. These actions potentiate the effect ofprostacyclin (PGI2), which acts as an inhibitor to plateletaggregation.